PROVAL #3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROVAL #3 (PROVAL #3).
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
| Metabolism | Acetaminophen: primarily hepatic via glucuronidation and sulfation, minor CYP2E1 and CYP3A4. Butalbital: hepatic via hydroxylation and glucuronidation, induces CYP450 enzymes. Caffeine: hepatic via CYP1A2 (major) and CYP3A4 (minor). |
| Excretion | Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites. |
| Half-life | 4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours). |
| Protein binding | 92–95% primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.0–3.0 L/kg, indicating extensive tissue distribution beyond total body water. |
| Bioavailability | Oral: 65–75% (first-pass metabolism). IM: 90–100%. IV: 100%. |
| Onset of Action | Oral: 30–60 minutes; IV: 5–10 minutes; IM: 15–30 minutes. |
| Duration of Action | 4–6 hours for oral and IM; 2–4 hours for IV; clinical effect correlates with plasma concentrations above minimum effective concentration. |
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
| Dosage form | CAPSULE |
| Renal impairment | Not recommended for use in patients with GFR <30 mL/min. For GFR 30-60 mL/min, reduce dose to 1 tablet every 6 hours; maximum 4 tablets per day. |
| Liver impairment | Contraindicated in Child-Pugh class C. For class A or B, limit to 1 tablet every 6 hours; maximum 4 tablets per day. |
| Pediatric use | Not recommended for children under 12 years. For ages 12-18, 1 tablet orally every 6 hours as needed; maximum 4 tablets per day. |
| Geriatric use | Start at 1 tablet every 6 hours; maximum 4 tablets per day. Monitor renal function and avoid in those with GFR <30 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROVAL #3 (PROVAL #3).
| Breastfeeding | Butalbital: excreted into breast milk; M/P ratio not reported. May cause infant sedation, poor feeding. Acetaminophen: minimal excretion (M/P ~1.0); compatible at recommended doses. Caffeine: M/P ~0.5-0.8; may cause irritability in infants. Use with caution; avoid prolonged use or high doses. Consider alternative analgesic. |
| Teratogenic Risk | PROVAL #3 contains butalbital (C-II), acetaminophen, and caffeine. Butalbital is pregnancy category D; associated with neonatal withdrawal and floppy infant syndrome if used in 3rd trimester. Acetaminophen is category B; risk only with overdose. Caffeine is category C; limited data suggests no major malformations but avoid high doses. 1st trimester: possible association with neural tube defects (butalbital). 2nd and 3rd trimesters: risk of preterm labor, low birth weight, neonatal sedation, withdrawal (butalbital). Avoid in labor due to neonatal respiratory depression. |
■ FDA Black Box Warning
Acetaminophen may cause severe liver injury, potentially fatal; do not exceed 4 grams per day (or less if hepatic impairment or alcohol use).
| Serious Effects |
Hypersensitivity to any component; acute intermittent porphyria; severe hepatic impairment; concurrent use of barbiturates with other CNS depressants may cause additive effects; avoid in patients with severe renal impairment.
| Precautions | Hepatotoxicity with acetaminophen overdose; sedation and respiratory depression with butalbital; caffeine may exacerbate anxiety, insomnia, or cardiac conditions; risk of drug dependence with barbiturates. |
Loading safety data…
| Fetal Monitoring | Monitor maternal CNS depression, respiratory status, hepatic function (acetaminophen) and caffeine levels. Fetal monitoring: nonstress test and biophysical profile if used chronically. Neonatal monitoring: observe for signs of withdrawal (irritability, seizures) and respiratory depression. |
| Fertility Effects | Butalbital may induce hepatic enzymes affecting sex hormones; potential reversible menstrual irregularities and reduced fertility. Acetaminophen: no known significant fertility effects. Caffeine: high intake may delay conception; avoid >200–300 mg/day. |